IDeate-Prostate01 is a study comparing an investigational drug to docetaxel, which is a standard chemotherapy in men with metastatic castration-resistant prostate cancer (mCRPC).

IDeate-Prostate02 is a study, in which the investigational drug, is given alone or in combination with standard treatments for prostate cancer. This study is also trying to find a recommended dose of the investigational drug.

Join Dr. Rana Mckay, who is a Professor of Medicine, Urology, and Radiation Medicine at the University of California, San Diego, where she serves as Associate Director of Clinical Sciences and Co-Leader of the Genitourinary Oncology Program at Moores Cancer Center, and is an investigator of the IDeate-Prostate trials, as she explains:

• The investigational study drug
• What investigational study drugs are the IDeate-Prostate clinical trials researching
• Who can qualify and if eligible, how to join the study